ACM
CLVS

Atika Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Atika Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-29,000
Closed -$2.71M – 98
2017
Q2 		$2.71M Sell
29,000
-21,000
-42% -$1.28M 0.95% 40
2017
Q1 		$3.18M Buy
50,000
+8,000
+19% +$486K 1.56% 24
2016
Q4 		$1.87M Buy
+42,000
New +$1.48M 1.11% 38
2015
Q4 		– Sell
-91,500
Closed -$8.41M – 75
2015
Q3 		$8.41M Buy
91,500
+54,500
+147% +$4.72M 4.13% 6
2015
Q2 		$3.25M Buy
37,000
+12,500
+51% +$1.07M 1.46% 28
2015
Q1 		$1.82M Buy
+24,500
New +$1.73M 1.21% 39

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atika Capital Management's CLVS Position: Q3 2017 in Review

Atika Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 29,000 shares — an estimated $2.71M sold.

Atika Capital Management first reported a position in CLVS in Q1 2015 and held it in 6 quarters. The position peaked at $8.41M in Q3 2015. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Atika Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Atika Capital Management sold 29,000 Clovis Oncology, Inc. shares in Q3 2017, an estimated $2.71M.
  • Atika Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 6 quarters.
  • Atika Capital Management's Clovis Oncology, Inc. position peaked at $8.41M in Q3 2015.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Atika Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.